米拉贝隆与索利那新治疗多发性硬化伴膀胱过度活动症症状的比较研究
两组达到OAB-q SF症状严重度MCID的比例相近(70% vs 69%),索利那新组OAB-q SF评分下降更显著,但便秘加重,米拉贝隆组便秘改善。
要点
- 多发性硬化伴膀胱过度活动症患者中,米拉贝隆与索利那新达到症状严重度MCID的比例相近。
- 索利那新组OAB-q SF评分下降更显著,但便秘加重风险需权衡。
- 米拉贝隆组便秘改善,索利那新组30%患者便秘加重超过MCID阈值。
核心结论
- 在多发性硬化伴膀胱过度活动症症状患者中,米拉贝隆与索利那新的患者报告结局应答率相近,约50%-70%达到各量表MCID。
- 索利那新短期内改善尿路症状严重度更明显,但需权衡便秘加重的风险。
研究设计与样本
- 第1-2年入组者处方米拉贝隆,第3-4年入组者处方索利那新,入组时及6周随访时完成患者报告结局量表。
主要发现
- 米拉贝隆组70%、索利那新组69%达到OAB-q SF症状严重度MCID。
- 索利那新组研究结束时OAB-q SF评分下降更显著(Δ=-37.87 vs -20.43,P=.02)。
- 便秘在米拉贝隆组改善、索利那新组加重(ΔPAC-SYM=-0.38 vs +0.22;P=.02),30%使用索利那新的患者便秘加重超过MCID阈值。
关键数值与推荐
- 主要结局为OAB-q SF症状严重度变化及MCID达成情况,便秘用PAC-SYM评估。
- 索利那新组OAB-q SF评分变化Δ=-37.87,米拉贝隆组Δ=-20.43,P=.02。
- PAC-SYM变化Δ=-0.38(米拉贝隆)vs +0.22(索利那新),P=.02。
临床怎么用
- 多发性硬化伴膀胱过度活动症症状患者选择药物时,应同时考虑症状改善程度与便秘风险。
- 对便秘风险较高的患者,米拉贝隆可能更有利于肠道功能。
- 索利那新可能在短期尿路症状严重度改善上更明显,需个体化权衡。
局限性
- 随访仅6周,为短期证据,需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the patient-perceived effectiveness and tolerability of mirabegron compared to solifenacin in a multiple sclerosis (MS) population with overactive bladder (OAB) symptoms. MATERIALS AND METHODS: MS patients with OAB symptoms who were not on medication for their urinary symptoms at enrollment were prospectively recruited. Patients enrolled in years 1-2 were prescribed mirabegron, whereas patients enrolled in years 3-4 were prescribed solifenacin. At enrollment and 6-week follow-up, patients completed several patient reported outcome measures. The primary outcome was change in OAB Questionnaire Short Form (OAB-q SF) symptom severity and minimal clinically important difference (MCID) achievement. The Patient Assessment of Constipation Symptoms (PAC-SYM) was used to assess bowel function over the treatment period. RESULTS: Sixty-one patients were enrolled. The majority of the mirabegron (70%) and the solifenacin (69%) group achieved the OAB-q SF symptom severity MCID. The solifenacin group had a statistically significant greater decrease in its end of study OAB-q SF score (Δ = -37.87 vs -20.43, P = .02). Constipation improved in the mirabegron group and worsened in the solifenacin group (ΔPAC-SYM = -0.38 vs +0.22; P = .02), with 30% of patients prescribed solifenacin experiencing worsening above the MCID threshold. CONCLUSION: Among MS patients, we demonstrated similar response rates to mirabegron and solifenacin, with approximately 50%-70% achieving each patient reported outcome measure's MCID. Though this small study showed some short-term evidence that improvement in urinary symptom severity was greater with solifenacin, this potential benefit must be weighed against the observed risk of worsening constipation. Further studies are needed to confirm these findings.
引用
- Brucker BM, Jericevic D, Rude T, et al. Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study. Urology. 2020. PMID: 32822687. doi:10.1016/j.urology.2020.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。